NEFL and myeloid sarcoma: This finding of serum NfL as a biomarker of MS disease activity was later substantiated with higher sensitivity Simoa digital immunoassay (Hansson et al., 2017; Novakova et al., 2017; Kuhle et al., 2019; Szilasiova et al., 2021).